HRP20220114T1 - Spojevi s anti-tumoralnim djelovanjem - Google Patents
Spojevi s anti-tumoralnim djelovanjem Download PDFInfo
- Publication number
- HRP20220114T1 HRP20220114T1 HRP20220114TT HRP20220114T HRP20220114T1 HR P20220114 T1 HRP20220114 T1 HR P20220114T1 HR P20220114T T HRP20220114T T HR P20220114TT HR P20220114 T HRP20220114 T HR P20220114T HR P20220114 T1 HRP20220114 T1 HR P20220114T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- ethoxymethyl
- methyl
- oxazol
- amine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 13
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- -1 oxotriazolyl Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 208000014951 hematologic disease Diseases 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- QRCSISPIJNVFQQ-MRXNPFEDSA-N (5R)-1-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-oxazol-5-yl]phenyl]-5-methylimidazolidin-2-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1C(NC[C@H]1C)=O)C QRCSISPIJNVFQQ-MRXNPFEDSA-N 0.000 claims 1
- GSYUXXIWIAFEEC-UHFFFAOYSA-N 1-(2-aminoethyl)-3-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-oxazol-5-yl]phenyl]imidazolidin-2-one Chemical compound NCCN1C(N(CC1)C1=CC=C(C=C1)C1=CN=C(O1)NC1=C(C=CC(=C1)COCC)C)=O GSYUXXIWIAFEEC-UHFFFAOYSA-N 0.000 claims 1
- SBJGWUJYRDHDBQ-UHFFFAOYSA-N 1-[4-[2-[3,5-bis(ethoxymethyl)anilino]-1,3-oxazol-5-yl]phenyl]imidazolidin-2-one Chemical compound CCOCC1=CC(NC2=NC=C(O2)C2=CC=C(C=C2)N2CCNC2=O)=CC(COCC)=C1 SBJGWUJYRDHDBQ-UHFFFAOYSA-N 0.000 claims 1
- FIJFTLZRJFJJHH-UHFFFAOYSA-N 1-[4-[2-[3-(ethoxymethyl)-5-(2-hydroxyethoxy)anilino]-1,3-oxazol-5-yl]phenyl]imidazolidin-2-one Chemical compound CCOCC1=CC(OCCO)=CC(NC2=NC=C(O2)C2=CC=C(C=C2)N2CCNC2=O)=C1 FIJFTLZRJFJJHH-UHFFFAOYSA-N 0.000 claims 1
- RQPXDZRYAPBRHH-UHFFFAOYSA-N 1-[4-[2-[3-(ethoxymethyl)-5-(2-methoxyethoxy)anilino]-1,3-oxazol-5-yl]phenyl]imidazolidin-2-one Chemical compound CCOCC1=CC(OCCOC)=CC(NC2=NC=C(O2)C2=CC=C(C=C2)N2CCNC2=O)=C1 RQPXDZRYAPBRHH-UHFFFAOYSA-N 0.000 claims 1
- LLZOOVAINRMGQZ-UHFFFAOYSA-N 1-[4-[2-[3-(ethoxymethyl)-5-methylanilino]-1,3-oxazol-5-yl]phenyl]imidazolidin-2-one Chemical compound C(C)OCC=1C=C(C=C(C=1)C)NC=1OC(=CN=1)C1=CC=C(C=C1)N1C(NCC1)=O LLZOOVAINRMGQZ-UHFFFAOYSA-N 0.000 claims 1
- LAKSUMNYPLRTDS-UHFFFAOYSA-N 1-[4-[2-[3-(ethoxymethyl)-5-methylanilino]-1,3-thiazol-4-yl]phenyl]imidazolidin-2-one Chemical compound C(C)OCC=1C=C(C=C(C=1)C)NC=1SC=C(N=1)C1=CC=C(C=C1)N1C(NCC1)=O LAKSUMNYPLRTDS-UHFFFAOYSA-N 0.000 claims 1
- QGBQAFISZCLPMZ-UHFFFAOYSA-N 1-[4-[2-[3-(ethoxymethyl)anilino]-1,3-oxazol-5-yl]phenyl]imidazolidin-2-one Chemical compound CCOCC1=CC=CC(NC2=NC=C(O2)C2=CC=C(C=C2)N2CCNC2=O)=C1 QGBQAFISZCLPMZ-UHFFFAOYSA-N 0.000 claims 1
- ZXWMOVQGEFDBGU-UHFFFAOYSA-N 1-[4-[2-[3-(ethoxymethyl)anilino]-1,3-thiazol-4-yl]phenyl]imidazolidin-2-one Chemical compound CCOCC1=CC=CC(NC2=NC(=CS2)C2=CC=C(C=C2)N2CCNC2=O)=C1 ZXWMOVQGEFDBGU-UHFFFAOYSA-N 0.000 claims 1
- HFPQVVDIBFNORW-UHFFFAOYSA-N 1-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-oxazol-5-yl]phenyl]-3-methylimidazolidin-2-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1C(N(CC1)C)=O)C HFPQVVDIBFNORW-UHFFFAOYSA-N 0.000 claims 1
- ZBAFYGYLXHEICJ-UHFFFAOYSA-N 1-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-oxazol-5-yl]phenyl]imidazolidin-2-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1C(NCC1)=O)C ZBAFYGYLXHEICJ-UHFFFAOYSA-N 0.000 claims 1
- WPTJLPQUUQBCGM-UHFFFAOYSA-N 1-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-oxazol-5-yl]phenyl]pyridin-2-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1C(C=CC=C1)=O)C WPTJLPQUUQBCGM-UHFFFAOYSA-N 0.000 claims 1
- ILSJJAHMDZLZCZ-UHFFFAOYSA-N 1-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-oxazol-5-yl]phenyl]pyrrolidin-2-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1C(CCC1)=O)C ILSJJAHMDZLZCZ-UHFFFAOYSA-N 0.000 claims 1
- HKHLLEPTTVBSDM-UHFFFAOYSA-N 1-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-thiazol-4-yl]phenyl]imidazolidin-2-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1SC=C(N=1)C1=CC=C(C=C1)N1C(NCC1)=O)C HKHLLEPTTVBSDM-UHFFFAOYSA-N 0.000 claims 1
- YYHQBSIXIZKFNY-UHFFFAOYSA-N 1-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-thiazol-5-yl]phenyl]imidazolidin-2-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1SC(=CN=1)C1=CC=C(C=C1)N1C(NCC1)=O)C YYHQBSIXIZKFNY-UHFFFAOYSA-N 0.000 claims 1
- VOKVJCQSCHSFJP-UHFFFAOYSA-N 1-[4-[5-[5-(ethoxymethyl)-2-methylanilino]-1,2,4-thiadiazol-3-yl]phenyl]imidazolidin-2-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC1=NC(=NS1)C1=CC=C(C=C1)N1C(NCC1)=O)C VOKVJCQSCHSFJP-UHFFFAOYSA-N 0.000 claims 1
- XGESFNUMDHJAJS-UHFFFAOYSA-N 1-[4-[5-[5-(ethoxymethyl)-2-methylanilino]-1,3,4-oxadiazol-2-yl]phenyl]imidazolidin-2-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC1=NN=C(O1)C1=CC=C(C=C1)N1C(NCC1)=O)C XGESFNUMDHJAJS-UHFFFAOYSA-N 0.000 claims 1
- GVJOWQGYKUBCQE-UHFFFAOYSA-N 2-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-oxazol-5-yl]phenyl]-4H-1,2,4-triazol-3-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=CNC1=O)C GVJOWQGYKUBCQE-UHFFFAOYSA-N 0.000 claims 1
- JSWUEYLOGRTPSD-UHFFFAOYSA-N 3-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-oxazol-5-yl]phenyl]-1H-pyridin-2-one Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)C=1C(NC=CC=1)=O)C JSWUEYLOGRTPSD-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- JNBIUWYKWYDSPW-UHFFFAOYSA-N N-[2-[3-[4-[2-[5-(ethoxymethyl)-2-methylanilino]-1,3-oxazol-5-yl]phenyl]-2-oxoimidazolidin-1-yl]ethyl]acetamide Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1C(N(CC1)CCNC(C)=O)=O)C JNBIUWYKWYDSPW-UHFFFAOYSA-N 0.000 claims 1
- QRSGFQDESJIFLU-UHFFFAOYSA-N N-[3,5-bis(ethoxymethyl)phenyl]-5-(4-pyrazol-1-ylphenyl)-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=C(C=C(C=1)COCC)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=CC=C1 QRSGFQDESJIFLU-UHFFFAOYSA-N 0.000 claims 1
- WUCHRJRDCNDMFS-UHFFFAOYSA-N N-[3-(ethoxymethyl)-5-methylphenyl]-5-(4-pyrazol-1-ylphenyl)-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=C(C=C(C=1)C)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=CC=C1 WUCHRJRDCNDMFS-UHFFFAOYSA-N 0.000 claims 1
- ANBIJEYNXHJRIP-UHFFFAOYSA-N N-[3-(ethoxymethyl)phenyl]-5-(4-pyrazol-1-ylphenyl)-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=C(C=CC=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=CC=C1 ANBIJEYNXHJRIP-UHFFFAOYSA-N 0.000 claims 1
- ZPQNZRRKCVTTFS-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-4-(4-pyrazol-1-ylphenyl)-1,3-thiazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1SC=C(N=1)C1=CC=C(C=C1)N1N=CC=C1)C ZPQNZRRKCVTTFS-UHFFFAOYSA-N 0.000 claims 1
- RMOPBHDDDOXMEO-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-(4-imidazol-1-ylphenyl)-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1C=NC=C1)C RMOPBHDDDOXMEO-UHFFFAOYSA-N 0.000 claims 1
- NCICENINCLNAMJ-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-(4-pyrazol-1-ylphenyl)-1,3,4-oxadiazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=NN=1)C1=CC=C(C=C1)N1N=CC=C1)C NCICENINCLNAMJ-UHFFFAOYSA-N 0.000 claims 1
- CIPHHAYPPQTPKX-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-(4-pyrazol-1-ylphenyl)-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=CC=C1)C CIPHHAYPPQTPKX-UHFFFAOYSA-N 0.000 claims 1
- ZPMUGFCTFPDKHI-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-(4-pyrazol-1-ylphenyl)-1,3-thiazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1SC(=CN=1)C1=CC=C(C=C1)N1N=CC=C1)C ZPMUGFCTFPDKHI-UHFFFAOYSA-N 0.000 claims 1
- CHNMIPRFUCPMKF-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-(4-pyridin-2-ylphenyl)-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)C1=NC=CC=C1)C CHNMIPRFUCPMKF-UHFFFAOYSA-N 0.000 claims 1
- VXTMJCUGYPDWOT-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(1,2,4-triazol-1-yl)phenyl]-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=CN=C1)C VXTMJCUGYPDWOT-UHFFFAOYSA-N 0.000 claims 1
- LJSZVNPEBAZKPB-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(1,3-thiazol-2-yl)phenyl]-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)C=1SC=CN=1)C LJSZVNPEBAZKPB-UHFFFAOYSA-N 0.000 claims 1
- QGUZRIQSXXKNJL-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(1H-pyrazol-4-yl)phenyl]-1,3-oxazol-2-amine Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)C1=CN=C(O1)NC1=C(C=CC(=C1)COCC)C QGUZRIQSXXKNJL-UHFFFAOYSA-N 0.000 claims 1
- KAFCXUQOMWBXEU-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(1H-pyrazol-5-yl)phenyl]-1,3-oxazol-2-amine Chemical compound N1N=CC=C1C1=CC=C(C=C1)C1=CN=C(O1)NC1=C(C=CC(=C1)COCC)C KAFCXUQOMWBXEU-UHFFFAOYSA-N 0.000 claims 1
- PCSPJWVWQVRWNQ-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(2-methylpyrazol-3-yl)phenyl]-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)C1=CC=NN1C)C PCSPJWVWQVRWNQ-UHFFFAOYSA-N 0.000 claims 1
- HVDYDLAZKVAIDL-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(3-methoxypyrazol-1-yl)phenyl]-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=C(C=C1)OC)C HVDYDLAZKVAIDL-UHFFFAOYSA-N 0.000 claims 1
- IDSVPEUUTLWJBT-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(3-methylpyrazol-1-yl)phenyl]-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=C(C=C1)C)C IDSVPEUUTLWJBT-UHFFFAOYSA-N 0.000 claims 1
- URNDZGDIXCGGGO-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(4-methylpyrazol-1-yl)phenyl]-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=CC(=C1)C)C URNDZGDIXCGGGO-UHFFFAOYSA-N 0.000 claims 1
- WDXVGLKCUPRDAT-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(5-methylpyrazol-1-yl)phenyl]-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=CC=C1C)C WDXVGLKCUPRDAT-UHFFFAOYSA-N 0.000 claims 1
- HEMVWJHGOITMEG-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(triazol-1-yl)phenyl]-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=NC=C1)C HEMVWJHGOITMEG-UHFFFAOYSA-N 0.000 claims 1
- VYVOOYRFWHJRTD-UHFFFAOYSA-N N-[5-(ethoxymethyl)-2-methylphenyl]-5-[4-(triazol-2-yl)phenyl]-1,3-oxazol-2-amine Chemical compound C(C)OCC=1C=CC(=C(C=1)NC=1OC(=CN=1)C1=CC=C(C=C1)N1N=CC=N1)C VYVOOYRFWHJRTD-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- 150000003016 phosphoric acids Chemical class 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 150000003460 sulfonic acids Chemical class 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15154028.3A EP3053920B1 (en) | 2015-02-05 | 2015-02-05 | Compounds with anti-tumoral activity |
| PCT/EP2016/052523 WO2016124747A1 (en) | 2015-02-05 | 2016-02-05 | Compounds with anti-tumoral activity |
| EP16703138.4A EP3253749B1 (en) | 2015-02-05 | 2016-02-05 | Compounds with anti-tumoral activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220114T1 true HRP20220114T1 (hr) | 2022-04-15 |
Family
ID=52450012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220114TT HRP20220114T1 (hr) | 2015-02-05 | 2016-02-05 | Spojevi s anti-tumoralnim djelovanjem |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10570122B2 (enExample) |
| EP (2) | EP3053920B1 (enExample) |
| JP (1) | JP6713000B2 (enExample) |
| KR (1) | KR102544132B1 (enExample) |
| CN (1) | CN107531685B (enExample) |
| AR (1) | AR103629A1 (enExample) |
| AU (1) | AU2016214283B2 (enExample) |
| BR (1) | BR112017016883B1 (enExample) |
| CA (1) | CA2975644C (enExample) |
| CY (1) | CY1124948T1 (enExample) |
| DK (1) | DK3253749T3 (enExample) |
| ES (2) | ES2796276T3 (enExample) |
| HR (1) | HRP20220114T1 (enExample) |
| HU (1) | HUE059063T2 (enExample) |
| IL (1) | IL253779A0 (enExample) |
| LT (1) | LT3253749T (enExample) |
| MX (1) | MX377742B (enExample) |
| PL (1) | PL3253749T3 (enExample) |
| PT (1) | PT3253749T (enExample) |
| RS (1) | RS62901B1 (enExample) |
| RU (1) | RU2758259C2 (enExample) |
| TW (1) | TWI748938B (enExample) |
| WO (1) | WO2016124747A1 (enExample) |
| ZA (1) | ZA201705537B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018106643A1 (en) * | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| CN109467531A (zh) * | 2017-09-08 | 2019-03-15 | 沈阳科创化学品有限公司 | 一种取代吡啶二羧酸衍生物的制备方法 |
| CN112225733B (zh) * | 2020-11-25 | 2022-12-09 | 湖南科技大学 | 一种含1,3,4-噻二唑吡啶-2-酮衍生物的制备方法和作为抗癌药物的应用 |
| US12502854B2 (en) | 2022-09-27 | 2025-12-23 | Illinois Tool Works Inc. | Tire repair system |
| AU2024225818A1 (en) * | 2023-02-24 | 2025-09-11 | Ab Science | Compounds for treating myeloid diseases with chromosomal abnormalities |
| CN117720459A (zh) * | 2023-12-26 | 2024-03-19 | 江苏希迪制药有限公司 | 一种阿贝西利中间体5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺制备工艺 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US810665A (en) * | 1905-10-10 | 1906-01-23 | Joseph Mlada | Mold for butter. |
| US1346834A (en) * | 1918-08-17 | 1920-07-20 | Charles E Mcmanus | Resilient rod |
| US3740420A (en) | 1967-11-28 | 1973-06-19 | Crown Zellerbach Corp | Pharmaceutical compositions with dimethyl sulfoxide |
| US3743727A (en) | 1970-11-16 | 1973-07-03 | Crown Zellerbach Corp | Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| CA1163561A (en) | 1979-11-06 | 1984-03-13 | Cyril Boroda | Preparation containing nitroglycerine and optionally other medicaments and preparation thereof |
| US4460372A (en) | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
| US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| US4411893A (en) | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
| CA1236029A (en) | 1984-05-14 | 1988-05-03 | Edmund Sandborn | Pharmaceutical solutions comprising dimethyl sulfoxide |
| US4615699A (en) | 1985-05-03 | 1986-10-07 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| GB9622363D0 (en) * | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
| US6448272B1 (en) * | 1998-12-07 | 2002-09-10 | Smithkline Beecham Corporation | Myt1 kinase inhibitors |
| JP4216947B2 (ja) * | 1999-05-18 | 2009-01-28 | 三井化学株式会社 | アミン化合物 |
| MXPA05001277A (es) * | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| CN102584813B (zh) * | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| ATE465731T1 (de) * | 2003-10-23 | 2010-05-15 | Ab Science | 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer |
| US20090196912A1 (en) | 2004-07-30 | 2009-08-06 | Gpc Botech Ag | Pyridinylamines |
| CA2578122A1 (en) * | 2004-08-27 | 2006-03-02 | Gpc Biotech Ag | Pyrimidine derivatives |
| MX2007012392A (es) * | 2005-04-04 | 2007-12-05 | Ab Science | Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa. |
| AU2006244203B2 (en) * | 2005-05-09 | 2012-05-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
| JP5214096B2 (ja) * | 2005-06-17 | 2013-06-19 | 富士フイルムファインケミカルズ株式会社 | 新規なビピリジン誘導体 |
| EP1904065A2 (en) * | 2005-07-14 | 2008-04-02 | AB Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
| AU2006290814B2 (en) * | 2005-09-13 | 2012-06-07 | Janssen Pharmaceutica N.V. | 2-aniline-4-aryl substituted thiazole derivatives |
| GB0524436D0 (en) * | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
| PT2402319T (pt) * | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
| JO3019B1 (ar) * | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| WO2007131953A1 (en) | 2006-05-12 | 2007-11-22 | Ab Science | A new process for the synthesis of 2-aminoxazole compounds |
| FR2901273B1 (fr) * | 2006-05-19 | 2010-12-24 | Anaconda Pharma | Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant |
| BRPI0806811A2 (pt) * | 2007-01-23 | 2011-09-13 | Palau Pharma Sa | derivados de purina |
| KR20090113382A (ko) * | 2007-02-22 | 2009-10-30 | 아이알엠 엘엘씨 | Ｇ 단백질-커플링된 수용체의 조절제로서의 티아졸 유도체 |
| GB0709031D0 (en) * | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| EP2310384B1 (en) * | 2008-07-09 | 2014-04-09 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| JP2012180281A (ja) * | 2009-06-29 | 2012-09-20 | Dainippon Sumitomo Pharma Co Ltd | 新規オキサジアゾール誘導体 |
| WO2011006903A1 (en) * | 2009-07-15 | 2011-01-20 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| EP2499282B1 (en) * | 2009-11-09 | 2015-04-22 | NeuroGenetic Pharmaceuticals, Inc. | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor |
| CN102812022B (zh) * | 2010-01-12 | 2016-02-03 | Ab科学有限公司 | 噻唑和噁唑激酶抑制剂 |
| GB201012105D0 (en) * | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| EP2616443A1 (en) * | 2010-09-14 | 2013-07-24 | Exelixis, Inc. | Phtalazine derivatives as jak1 inhibitors |
| WO2012068210A1 (en) * | 2010-11-18 | 2012-05-24 | Janssen Pharmaceutica Nv | Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| WO2012162461A1 (en) * | 2011-05-25 | 2012-11-29 | Janssen Pharmaceutica Nv | Phenyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation |
| WO2012166463A2 (en) * | 2011-05-27 | 2012-12-06 | Neosome Life Sciences, LLC | Aminooxazole inhibitors of cyclin dependent kinases |
| ES2573831T3 (es) * | 2011-07-27 | 2016-06-10 | Ab Science | Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit) |
| KR101896035B1 (ko) * | 2011-08-23 | 2018-09-07 | 덕산네오룩스 주식회사 | 유기전기소자용 신규 화합물, 이를 이용하는 유기전기소자 및 그 단말 |
| CN103436048B (zh) * | 2013-08-08 | 2014-12-03 | 陕西师范大学 | 硫脲供体双桥链有机染料及其应用 |
| US20150045353A1 (en) * | 2013-08-09 | 2015-02-12 | Neurogenetic Pharmaceuticals, Inc. | Formulations containing gamma secretase modulators, methods for preparation and delivery thereof |
| MX2016012460A (es) * | 2014-03-24 | 2017-05-04 | Ab Science | Derivados de oxazol sustituidos por diazaespiroalcanona como inhibidores de torosina quinasa de bazo. |
| EP3144307A1 (en) * | 2015-09-18 | 2017-03-22 | AB Science | Novel oxazole derivatives that inhibit syk |
-
2015
- 2015-02-05 ES ES15154028T patent/ES2796276T3/es active Active
- 2015-02-05 EP EP15154028.3A patent/EP3053920B1/en active Active
-
2016
- 2016-02-05 MX MX2017010157A patent/MX377742B/es active IP Right Grant
- 2016-02-05 ES ES16703138T patent/ES2905412T3/es active Active
- 2016-02-05 BR BR112017016883-9A patent/BR112017016883B1/pt active IP Right Grant
- 2016-02-05 CN CN201680008641.9A patent/CN107531685B/zh active Active
- 2016-02-05 CA CA2975644A patent/CA2975644C/en active Active
- 2016-02-05 PL PL16703138T patent/PL3253749T3/pl unknown
- 2016-02-05 EP EP16703138.4A patent/EP3253749B1/en active Active
- 2016-02-05 KR KR1020177022077A patent/KR102544132B1/ko active Active
- 2016-02-05 RU RU2017127484A patent/RU2758259C2/ru not_active Application Discontinuation
- 2016-02-05 AR ARP160100337A patent/AR103629A1/es unknown
- 2016-02-05 RS RS20220136A patent/RS62901B1/sr unknown
- 2016-02-05 WO PCT/EP2016/052523 patent/WO2016124747A1/en not_active Ceased
- 2016-02-05 AU AU2016214283A patent/AU2016214283B2/en active Active
- 2016-02-05 JP JP2017539023A patent/JP6713000B2/ja active Active
- 2016-02-05 HR HRP20220114TT patent/HRP20220114T1/hr unknown
- 2016-02-05 US US15/548,451 patent/US10570122B2/en active Active
- 2016-02-05 TW TW105103940A patent/TWI748938B/zh not_active IP Right Cessation
- 2016-02-05 LT LTEPPCT/EP2016/052523T patent/LT3253749T/lt unknown
- 2016-02-05 DK DK16703138.4T patent/DK3253749T3/da active
- 2016-02-05 HU HUE16703138A patent/HUE059063T2/hu unknown
- 2016-02-05 PT PT167031384T patent/PT3253749T/pt unknown
-
2017
- 2017-08-01 IL IL253779A patent/IL253779A0/en active IP Right Grant
- 2017-08-15 ZA ZA201705537A patent/ZA201705537B/en unknown
-
2022
- 2022-02-02 CY CY20221100089T patent/CY1124948T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017127484A (ru) | Соединение, фармацевтическая композиция, лекарственное средство | |
| RU2016133626A (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
| RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
| HRP20170352T1 (hr) | Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori | |
| CA2610888A1 (en) | Inhibitors of akt activity | |
| HRP20160421T1 (hr) | Derivat azola | |
| JP2010533158A5 (enExample) | ||
| RU2017134379A (ru) | Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4 | |
| HRP20160678T1 (hr) | Derivati 2-(1,2,3-triazol-2-il)benzamida i 3-(1,2,3-triazol-2-il)pikolinamida kao antagonisti receptora oreksina | |
| HRP20231614T1 (hr) | Spojevi pirolotriazina kao tam inhibitori | |
| HRP20180382T1 (hr) | Inhibitori protein kinaze | |
| JP2014525444A5 (enExample) | ||
| RU2011134631A (ru) | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2017506237A5 (enExample) | ||
| RU2012143794A (ru) | Производные n-(имидазопиримидин-7-ил)-гетероаламидов и их применение в качестве ингибиторов pde10a | |
| JP2003525872A5 (enExample) | ||
| JP2017530185A5 (enExample) | ||
| CA2522024A1 (en) | Cgrp receptor antagonists | |
| RU2015104962A (ru) | Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков | |
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| JP2016540811A5 (enExample) | ||
| HRP20191554T1 (hr) | Derivat azol benzena | |
| RU2016111138A (ru) | Гетероциклические соединения и способы их применения |